ClinPhone Completes MHRA Inspection
ClinPhone shows commitment to Good Clinical Practice by completing the latest Medicines and Healthcare Products Regulatory Agency inspection.
Nottingham, UK-June 2, 2008-ClinPhone (www.clinphone.com), a Clinical Technology Organization (CTO), has received the GCP Inspection Statement to complete the latest Inspection by the GCP Inspectorate of the Medicines and Healthcare Products Regulatory Agency (MHRA).
The MHRA is an executive agency of the Department of Health and was established in April 2003 from a merger between the Medicines Control Agency and the Medical Devices Agency. The agency is responsible for ensuring that medicines and medical devices work and are acceptably safe.
As with any organization involved in the clinical trials process, ClinPhone has implemented rigorous procedures to ensure compliance with Good Clinical Practice (GCP). These are assessed by clients, who conduct in excess of 40 audits per year at ClinPhone, as well as by Regulatory Authorities.
In the UK, ClinPhone is subject to inspection by the MHRA, in accordance with ‘The Medicines for Human Use (Clinical Trials) Regulations’ (Statutory Instruments 2004/1031 as amended). ClinPhone underwent their second routine GCP Inspection in mid-November 2007. Following submission of responses to the Inspection Report, a revised GCP Inspection Statement, signifying the completion of the latest inspection cycle, was received on 23rd April 2008.
Steve Kent, chief executive officer of ClinPhone, comments, “This reinforces to our clients that ClinPhone are fully committed to Good Clinical Practice. We have the appropriate policies and procedures in place, as well as robust technology with sufficient back-up systems, to successfully manage our clients’ studies to the very highest standards.”
To find out more about the Medicines and Healthcare Products Regulatory Agency (MHRA), please visit: www.mhra.gov.uk/aboutus/index.htm.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Merck Stops HYPERION Trial for Winrevair in PAH Following Positive ZENITH Trial Results
January 30th 2025The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial hypertension, making it unethical to continue.
